Medical Funding Professionals (MFP) is pleased to announce that McGinley Orthopedics has engaged MFP to implement the Capital Planning Valuation Strategy™ Co-Chaired by Scott Pantel of LSI and Stephen Brock of MFP in preparation of the company’s Regulation A+ offering.

McGinley Orthopedics is a commercial-stage surgical device company developing orthopedic devices with the goal of increasing patient safety and physician confidence. The company’s patented IntelliSense® orthopedic power tools employ proprietary sensing, navigation, and robotics capabilities providing surgeons with precise depth measurements and accurate screw sizing in real-time. McGinley’s innovative technology has the potential to transform the standard of care in the orthopedic industry, reducing surgery time and cost while improving patient outcomes and potentially eliminating the need for repeat surgeries to correct screw placement and size.   

“Our mission is to push the frontier of orthopedic power tool innovation,” says McGinley founder Joseph McGinley, PhD, MD. “Conventional devices lack sensing and real-time data recording abilities and force surgeons to rely on feel to avoid plunging into the patient’s blood vessels, tendons, and other structures. The ability to read depth and detect bone through AI is a significant breakthrough that will deliver considerable benefits to both surgeons and patients.” 

McGinley Orthopedics was named one of MedTech Outlook’s “Top Ten Solutions Providers” in 2019 and its products and 137 patents have attracted interest from leading orthopedic device makers in the US, including an offer of acquisition. The company is engaged in partnering discussions with several organizations related to technological development, licensing, commercialization, and distribution in various segments of the national and global orthopedic power tool and implant markets.

Watch McGinley Orthopedics, CEO, Joseph McGinley's Investor Presentation at LSI USA '22

McGinley Orthopedics recently received FDA clearance for its second product, Lever Action Plate System®, the only patented distal radius plate on the market providing three-dimensional treatment of wrist fractures, and has several new products and technologies under development which promise to advance orthopedic medicine and improve patient outcomes. Eventually the company plans to transition the surgical tool manufacturing industry to the newer, larger, and more rapidly-growing market for AI and robot-assisted surgical devices and implants. 

“We are disrupters in this industry with huge ambitions,” continues McGinley. “We want to expand our products globally and develop new cutting-edge technologies that change the way surgery is performed. To accomplish this, we need more than just money – we need a strategic plan for capital to see us through new product development as we increase investments in sales and marketing resources. That’s what Medical Funding Professionals brings to the table, and we look forward to working with them to reach these objectives.” 

“We’re so excited to be working with McGinley,” says Medical Funding Professionals CEO Stephen Brock. “Orthopedic surgeries are time-consuming, costly, and potentially risky to patients. We see it as our mission to get McGinley’s revolutionary technology in the hands of surgeons for the benefit of patients and healthcare providers worldwide.”

“Companies like McGinley are what make the medtech industry so fascinating,” says Scott Pantel, CEO of medtech market research firm Life Science Intelligence, an MFP strategic partner. “McGinley is transforming orthopedic procedures and the benefits are clear to see. I’ll be watching them closely as they continue to develop and grow.”

McGinley will be among 100 vetted presenting companies attending the LSI Europe ’22 Emerging Medtech Summit in London taking place on September 21-24, 2022. In addition to company presentations, the event will feature panel sessions with investors, one-on-one meetings, and vast networking opportunities with leading medtech investors, strategics, and industry insiders. 

About McGinley Orthopedics
McGinley Orthopedics, a commercial stage surgical device company, was founded in 2012 with the goal of increasing patient safety and physician confidence through technological advances in the orthopedic field. The IntelliSense Drill Technology®, McGinley's flagship product, was conceived by Dr. Joseph McGinley, CEO and Founder of McGinley Orthopedics; Dr. Scott Kozin, and Scott Porter. McGinley received FDA clearance of its IntelliSense Drill Technology® in 2015 and several new products have been developed that also advance orthopedic medicine and improve patient outcomes, including the newly FDA-Cleared Lever Action Plate System® providing a novel solution for wide range of distal radius fractures. The Company aims to make its growing product line the standard of care in the orthopedic industry.

McGinley Orthopedics is considering an offering of securities exempt from registration under the Securities Act of 1933. No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until McGinley determines the exemption under which the offering is intended to be conducted and, where applicable, the filing, disclosure, or qualification requirements of such exemption are met.  A person's indication of interest involves no obligation or commitment of any kind.

About Medical Funding Professionals
Medical Funding Professionals is a registered investment advisor firm providing capital and cash flow planning solutions to the medical industry, including life sciences, biotech, medtech, and pharmaceutical sectors. Their Capital Planning Valuation Strategy™ (CPVS) ensures founders and key executives maintain control of their companies as they raise capital and grow. Medical Funding Professionals compliments its advisory services by providing further guidance on how to utilize the updated private company exemptions such as 506c for accredited investors and Reg A+ which allows a company to raise up to $75M from both accredited and non-accredited every 12 months.

About Life Science Intelligence
LSI is a medical technology-focused market intelligence & consulting company that helps medtech executives make informed strategic decisions by better understanding market dynamics, trends, opportunities and the competitive landscape.

Regulation A+ Disclaimer

This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply:

• No money or other consideration is being solicited, and if sent in response, will not be accepted;
• No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date;
• A person’s indication of interest involves no obligation or commitment of any kind; and 
• An offering statement, which would include a preliminary offering circular, has not yet been filed with the SEC.